A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Summary

To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.

Conditions

• Ovarian Cancer
• Peritoneal Neoplasms

Interventions

DRUG

Volociximab

15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops

Sponsors & Collaborators

• Biogen

  collaborator INDUSTRY

• Facet Biotech

  lead INDUSTRY

Principal Investigators

• Carolyn Matthews, MD · Mary Crowley Medical Research Center

• Minal Barve, MD · Texas Oncology PA, Presbyterian

• James Burke, MD · Billings Clinic (MCMRC network)

• Dana Glenn, MD · Sharp Hospital

• Russell Schilder, MD · Fox Chase Cancer Center

• Nikki Spellman, MD · Indiana University

• Michael Gold, MD · Oklahoma University Health Science Center

• Richard Penson, MD · Massachusetts General Hospital

• Mark Einstein, MD · Montefiore Medical Center

• Robert Holloway, MD · Florida Hospital Cancer Institute

• Deborah Armstrong, MD · Johns Hopkins Kimmel Cancer Center

• Snehel Bhoola, MD · Memorial Health University Medical Center

• Eric Winquist, MD · London Health Sciences Center

• Ernst Lengyel, MD · University of Chicago

• John Glaspy, MD · UCLA JCCC Clinical Research Unit

• Krish Tewari, MD · UCI Medical Center

• C. William Helm, MD · James Graham Brown Cancer Center

• John Glaspy, MD · University of California, Los Angeles

• Michael Sawyer, MD · Cross Cancer Institute

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-08-31

Primary Completion

2008-04-30

Completion

2008-04-30

Countries

• United States
• Canada

Study Locations